These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 30804948)

  • 41. [The role of CD4+ CD25+ T cell and FOXP3 in hsot acute graft rejection].
    Liu YJ; Wu DP; Li CX; He J; Qiu QC; Zhang XG
    Zhonghua Nei Ke Za Zhi; 2006 Oct; 45(10):835-8. PubMed ID: 17217750
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune recovery after in vivo T-cell depletion myeloablative conditioning hematopoietic stem cell transplantation in severe beta-thalassemia children.
    Qin F; Shi L; Li Q; Zhang Z; Liu L; Li J; Yang G; Lai YR
    Eur J Haematol; 2019 Oct; 103(4):342-350. PubMed ID: 31276236
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Haploidentical hematopoietic stem cell transplantation in hematologic malignancies with G-CSF mobilized bone marrow plus peripheral blood stem cells grafts without T cell depletion: a single center report of 29 cases.
    Wang HX; Yan HM; Wang ZD; Xue M; Liu J; Guo ZK
    Leuk Lymphoma; 2012 Apr; 53(4):654-9. PubMed ID: 21929286
    [TBL] [Abstract][Full Text] [Related]  

  • 44. γδ T Cells May Aggravate Acute Graft-Versus-Host Disease Through CXCR4 Signaling After Allogeneic Hematopoietic Transplantation.
    Wu N; Liu R; Liang S; Gao H; Xu LP; Zhang XH; Liu J; Huang XJ
    Front Immunol; 2021; 12():687961. PubMed ID: 34335589
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differences in Aspergillus-specific immune recovery between T-cell-replete and T-cell-depleted hematopoietic transplants.
    Perruccio K; Topini F; Tosti A; Gazzola MV; Messina C; Martelli MF; Caniglia M; Velardi A; Cesaro S
    Eur J Haematol; 2015 Dec; 95(6):551-7. PubMed ID: 25688598
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
    Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rapid and effective CD3 T-cell depletion with a magnetic cell sorting program to produce peripheral blood progenitor cell products for haploidentical transplantation in children and adults.
    Dykes JH; Toporski J; Juliusson G; Békássy AN; Lenhoff S; Lindmark A; Scheding S
    Transfusion; 2007 Nov; 47(11):2134-42. PubMed ID: 17958543
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Negative depletion of α/β+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation.
    Locatelli F; Bauquet A; Palumbo G; Moretta F; Bertaina A
    Immunol Lett; 2013; 155(1-2):21-3. PubMed ID: 24091162
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Haploidentical HSCT for hemoglobinopathies: improved outcomes with TCRαβ
    Gaziev J; Isgrò A; Sodani P; Paciaroni K; De Angelis G; Marziali M; Ribersani M; Alfieri C; Lanti A; Galluccio T; Adorno G; Andreani M
    Blood Adv; 2018 Feb; 2(3):263-270. PubMed ID: 29431621
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CD34
    Mainardi C; Ebinger M; Enkel S; Feuchtinger T; Teltschik HM; Eyrich M; Schumm M; Rabsteyn A; Schlegel P; Seitz C; Schwarze CP; Müller I; Greil J; Bader P; Schlegel PG; Martin D; Holzer U; Döring M; Handgretinger R; Lang P
    Br J Haematol; 2018 Jan; 180(1):90-99. PubMed ID: 29205259
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Allogeneic hematopoietic stem-cell transplantation from haploidentical donors using 'ex-vivo' T-cell depletion in pediatric patients with hematological malignancies: state of the art review.
    González-Vicent M; Díaz Perez MA
    Curr Opin Oncol; 2018 Nov; 30(6):396-401. PubMed ID: 30307414
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R
    Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CD34 positive selection as prophylaxis against graft versus host disease in allogeneic peripheral blood stem cell transplantation.
    Butt NM; McGinnity N; Clark RE
    Leuk Lymphoma; 2003 Sep; 44(9):1509-13. PubMed ID: 14565652
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A promising sword of tomorrow: Human γδ T cell strategies reconcile allo-HSCT complications.
    Hu Y; Cui Q; Luo C; Luo Y; Shi J; Huang H
    Blood Rev; 2016 May; 30(3):179-88. PubMed ID: 26654098
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advanced flowcytometric analysis of regulatory T cells: CD127 downregulation early post stem cell transplantation and altered Treg/CD3(+)CD4(+)-ratio in severe GvHD or relapse.
    Bremm M; Huenecke S; Lehrnbecher T; Ponstingl E; Mueller R; Heinze A; Bug G; Quaiser A; Kapinsky M; Brehm C; Bader P; Schneider G; Klingebiel T; Koehl U
    J Immunol Methods; 2011 Oct; 373(1-2):36-44. PubMed ID: 21839739
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors.
    Hassan HT; Stockschläder M; Schleimer B; Krüger W; Zander AR
    Transpl Immunol; 1996 Dec; 4(4):319-23. PubMed ID: 8972563
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients.
    Heining C; Spyridonidis A; Bernhardt E; Schulte-Mönting J; Behringer D; Grüllich C; Jakob A; Bertz H; Finke J
    Bone Marrow Transplant; 2007 May; 39(10):613-22. PubMed ID: 17384658
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors.
    Barge RM; Osanto S; Marijt WA; Starrenburg CW; Fibbe WE; Nortier JW; Falkenburg JH; Willemze R
    Exp Hematol; 2003 Oct; 31(10):865-72. PubMed ID: 14550801
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors.
    Yan CH; Liu DH; Xu LP; Liu KY; Zhao T; Wang Y; Chen H; Chen YH; Han W; Huang XJ
    Clin Transplant; 2012; 26(6):868-76. PubMed ID: 22432715
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with nonmalignant disorders.
    Bertaina A; Merli P; Rutella S; Pagliara D; Bernardo ME; Masetti R; Pende D; Falco M; Handgretinger R; Moretta F; Lucarelli B; Brescia LP; Li Pira G; Testi M; Cancrini C; Kabbara N; Carsetti R; Finocchi A; Moretta A; Moretta L; Locatelli F
    Blood; 2014 Jul; 124(5):822-6. PubMed ID: 24869942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.